Device Panel Reforms: FDA Puts An End To Approvability Votes
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panel members will no longer take an up or down vote on the approvability of medical devices, or on recommended conditions of approval, CDRH announced April 26
You may also be interested in...
Further 'Slight Modifications' To Advisory Panel Process Likely
FDA's device center said it will continue to assess its advisory panel process, a week after the first two meetings were held without the traditional up-or-down vote on device approvability
Further 'Slight Modifications' To Advisory Panel Process Likely
FDA's device center said it will continue to assess its advisory panel process, a week after the first two meetings were held without the traditional up-or-down vote on device approvability
Panel Narrowly Recommends Medtronic Spine Treatment After Tough Scrutiny
An FDA advisory panel cast a mixed vote on July 27 in support of Medtronic's Amplify rhBMP-2 Matrix spinal treatment, reflecting disagreement about safety and the reliability of some clinical data